The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Larger Will The Positron Emission Tomography (PET) Nuclear Medicine Market Become By 2030 Compared To 2026?
The positron emission tomography (pet) nuclear medicine market has shown substantial growth in recent years. It is anticipated to expand from $13.16 billion in 2025 to $15.06 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.5%. The expansion observed in the past can be attributed to a rise in cancer diagnosis rates, an increase in nuclear medicine facilities, the broad utilization of f-18 radiotracers, an uptick in cardiology imaging applications, and enhancements in radiopharmaceutical production.
The positron emission tomography (pet) nuclear medicine market is anticipated to experience substantial growth in the upcoming years. Its valuation is projected to reach $25.7 billion by 2030, expanding at a compound annual growth rate (CAGR) of 14.3%. The drivers for this growth during the forecast period encompass heightened investments in molecular imaging, an escalating demand for personalized medicine diagnostics, the broadening of neurological imaging applications, advancements in radiotracer development, and the increasing adoption of hybrid imaging systems. Significant trends anticipated in the forecast period include a rising uptake of advanced radiotracers, the expanding application of PET imaging in oncology, greater integration of PET with CT and MRI systems, the diversification of precision diagnostic imaging applications, and an intensified focus on early disease detection.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19151&type=smp
What Major Growth Factors Are Impacting The Positron Emission Tomography (PET) Nuclear Medicine Market?
The rising occurrence of chronic diseases is anticipated to drive the expansion of the positron emission tomography (PET) nuclear medicine market moving forward. A chronic disease refers to an enduring health condition typically persisting for at least three months, which may necessitate continuous medical care or restrict daily activities. This increase in chronic illnesses stems from factors such as an aging population, insufficient physical activity, unhealthy dietary practices, and environmental risks. PET nuclear medicine aids in managing chronic diseases by providing sophisticated imaging methods that allow for prompt detection, accurate diagnosis, and consistent monitoring of these ailments. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, more than 35 million new cancer cases would arise, marking a 77% rise from the estimated 20 million cases in 2022. Thus, the growing prevalence of chronic diseases is a primary catalyst for the growth of the positron emission tomography (PET) nuclear medicine market.
How Are Different Segment Groups Identified Within The Positron Emission Tomography (PET) Nuclear Medicine Market?
The positron emission tomography (pet) nuclear medicine market covered in this report is segmented –
1) By Type: F-18, Rb-82, Other Types
2) By Procedure: Diagnostic Procedures, Hybrid PET CT Procedures, Positron Emission Tomography Procedures, Therapeutic Procedures, Beta Emitter Procedures, Alpha Emitter Procedures, Targeted Radiopharmaceutical Therapy
3) By Application: Oncology, Cardiology, Neurology, Other Applications
4) By End User: Hospitals, Diagnostic Centers, Research Institutes
Subsegments:
1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose), F-18 NaF (Sodium Fluoride), F-18 Fluorocholine
2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging, Rb-82 for Cardiac PET Stress Testing, Rb-82 for Other Cardiac Applications
3) By Other Types: C-11 (Carbon-11), N-13 (Nitrogen-13), O-15 (Oxygen-15), Ga-68 (Gallium-68)
Which Trends Are Influencing The Direction Of The Positron Emission Tomography (PET) Nuclear Medicine Market?
Key players in the portal hypertension management market are increasingly utilizing sophisticated minimally invasive devices to improve patient outcomes and mitigate procedural dangers. Such devices are medical instruments engineered to conduct procedures with minimal interference to adjacent tissues, typically via small cuts or natural bodily orifices. As an example, in November 2023, Medtronic Plc, a US-based medical device manufacturer, secured clearance from the U.S. Food and Drug Administration (FDA) for its Symplicity Spyral renal denervation (RDN) system. This particular system functions as a minimally invasive tool for managing hypertension. The cutting-edge procedure uses radiofrequency energy to target nerves situated close to the kidneys, effectively quieting them to aid in hypertension control.
Who Are The Prominent Players Across The Positron Emission Tomography (PET) Nuclear Medicine Market?
Major companies operating in the positron emission tomography (pet) nuclear medicine market are Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Shimadzu Corporation, Toshiba America Medical Systems Inc., Mediso Medical Imaging Systems Ltd., Lantheus Holdings Inc., Jubilant DraxImage Inc., Advanced Accelerator Applications, Eckert & Ziegler Strahlen- und Medizintechnik AG, Cardinal Health, NorthStar Medical Radioisotopes LLC, Bruker Corporation, Digirad Corporation, Neusoft Medical Systems Co. Ltd., Agfa HealthCare NV, Bayer AG, Positron Corporation
Access The Complete Positron Emission Tomography (PET) Nuclear Medicine Market Report:
Which Region Has The Strongest Presence In The Positron Emission Tomography (PET) Nuclear Medicine Market?
North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) nuclear medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Positron Emission Tomography (PET) Nuclear Medicine Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=19151&type=smp
Browse Through More Reports Similar to the Global Positron Emission Tomography (PET) Nuclear Medicine Market 2026, By The Business Research Company
Patient Portal Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/patient-portal-global-market-report
Ocular Hypertension Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/ocular-hypertension-treatment-global-market-report
Captive Portal Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/captive-portal-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
